Sponsors
Personalis, Tempus Partner to Commercialize Blood-Based Minimal Residual Disease Test
Tempus will market Personalis' NeXT Personal Dx liquid biopsy assay while Personalis completes its clinical validation in more indications.
Germany to Test Genomics-Based Precision Medicine for Cancer, Rare Disease in National Pilot Project
Premium
With reimbursement from public health insurance, the "model project" will run for at least five years and examine the utility of genomic sequencing for advanced cancer and rare disease patients.
Cardio Diagnostics Publishes Validation Data for Molecular Coronary Heart Disease Test
The new study in the Journal of the American Heart Association shows that the firm's machine learning-based genetic-epigenetic approach can help diagnose coronary heart disease.
AMP Petitions Congress to Revisit CLIA Update, Eyes Legal Action Against New Proposed FDA LDT Rule
While AMP asked members to register their opposition officially, one official said "there probably will be a lawsuit."
A comparison for 144 solid tumor samples showed a "high degree of alignment" with FoundationOne CDx and better calling of CNAs than Illumina's TSO 500.